ProShares UltraPro Short NASDAQ Biotechnology
ZBIO
ZBIO was delisted on the 27th of March, 2020.
7 hedge funds and large institutions have $2.08M invested in ProShares UltraPro Short NASDAQ Biotechnology in 2016 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 2 closing their positions.
67% more call options, than puts
Call options by funds: $3.83M | Put options by funds: $2.3M
13% less funds holding
Funds holding: 8 → 7 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
50% less capital invested
Capital invested by funds: $4.2M → $2.08M (-$2.12M)
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$277K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$31.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$653K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$465K |
| 3 |
Goldman Sachs
New York
|
-$316K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$173K |
| 5 |
Morgan Stanley
New York
|
-$158K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
1
Virtu Financial
New York
| $1.31M | +$277K | +4,498 | +29% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $354K | -$465K | -7,561 | -58% |
|
|
3
Morgan Stanley
New York
| $181K | -$158K | -2,574 | -48% |
|
|
4
Simplex Trading
Chicago,
Illinois
| $175K | -$173K | -2,811 | -51% |
|
|
5
UBS Group
Zurich,
Switzerland
| $33K | +$31.1K | +505 | New |
|
|
CG
6
Cutler Group
San Francisco,
California
| $29K | -$30.8K | -500 | -53% |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $1K | -$148K | -2,411 | -99% |
|
|
8
Jane Street
New York
| – | -$653K | -10,608 | Closed |
|
|
9
Goldman Sachs
New York
| – | -$316K | -4,367 | Closed |
|
ZBIO Hedge Fund Activity: Q2 2016 in Review
7 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) for Q2 2016, worth a combined $2.08M — down 50% from $4.2M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ZBIO and 1 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 1 added.
The largest buyer was Virtu Financial, adding an estimated $277K. The largest seller was Jane Street, exiting entirely with an estimated $653K sold.
- 7 institutional investors held ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) as of Q2 2016, down from 8 in Q1 2016.
- Funds reported $2.08M of ProShares UltraPro Short NASDAQ Biotechnology stock for Q2 2016, down 50% quarter-over-quarter.
- 1 fund opened new ProShares UltraPro Short NASDAQ Biotechnology positions in Q2 2016 and 2 closed out, a net change of -1 holder.
- The largest ProShares UltraPro Short NASDAQ Biotechnology buyer in Q2 2016 was Virtu Financial, an estimated $277K added.
- The largest ProShares UltraPro Short NASDAQ Biotechnology seller in Q2 2016 was Jane Street, an estimated $653K sold.
Based on aggregated 13F filings for Q2 2016.